

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
20 April 2023 (20.04.2023)



(10) International Publication Number
WO 2023/062222 A1

(51) International Patent Classification:

A61K 35/741 (2015.01) *C12N 1/20* (2006.01)
A61K 45/06 (2006.01) *A61K 39/00* (2006.01)
C07K 16/18 (2006.01) *A61P 35/00* (2006.01)

Published:

- with international search report (Art. 21(3))
- with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description (Rules 13bis.4(d)(i) and 48.2(a)(viii))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(21) International Application Number:

PCT/EP2022/078723

(22) International Filing Date:

14 October 2022 (14.10.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

21306448.8 15 October 2021 (15.10.2021) EP

(71) Applicant: **EXELIOM BIOSCIENCES** [FR/FR]; 67 rue des Godrans, 21000 DIJON (FR).

(72) Inventors: **SOKOL, Harry**; 25 rue Miollis, 75015 PARIS (FR). **RUFFIÉ, Pauline**; 26 rue Ernest Renan App6, 33400 Talence (FR). **HADIDA, Benjamin**; 7 Passage du chemin vert, 75011 PARIS (FR).

(74) Agent: **CABINET NONY**; 11 rue Saint-Georges, 75009 PARIS (FR).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: ASSOCIATION OF A *FAECALIBACTERIUM PRAUSNITZII* STRAIN AND ANTI-PD-1, ANTI-PD-L1 OR ANTI-CTLA-4 ANTIBODIES FOR THE TREATMENT OF CANCER

(57) Abstract: The present invention relates to an association of a *Faecalibacterium prausnitzii* bacterial strain deposited to the CNCM under the accession number I-4573; and at least one immune checkpoint inhibitor, in particular at least one monoclonal antibody selected from the group consisting of anti-PD-1, anti-PD-L1 and anti-CTLA-4 monoclonal antibodies for its use for preventing and/or treating a cancer in a mammal patient. The association as such is also considered.



WO 2023/062222 A1